ARA 290
$39.99
Out of stock
Product Description
ARA-290 (also known as Cibinetide) is an 11-amino-acid synthetic peptide derived from the tissue-protective region of erythropoietin (EPO). Unlike full-length EPO, ARA-290 was specifically engineered to activate tissue repair pathways without stimulating red blood cell production, making it a unique compound for laboratory investigation into inflammation, nerve biology, and regenerative mechanisms.
This compound is not intended for human or animal use, and is not designed for therapeutic, diagnostic, or clinical applications. All use must remain strictly within qualified research settings.
Important Notice
For research purposes only. Not for human or animal use & not FDA-approved.
By purchasing, you confirm you are 21 years of age or older and a qualified researcher.
Researchers commonly choose ARA-290 to investigate:
Innate Repair Receptor (IRR) signaling and its role in tissue protection
Inflammatory pathways involved in acute and chronic tissue injury
Peripheral nerve biology and mechanisms of nerve repair
Cellular resilience during oxidative or inflammatory stress
Regenerative medicine and tissue recovery models
Neurobiology and small fiber nerve function in experimental systems
Non-erythropoietic EPO derivatives, allowing study of protective signaling without increasing red blood cell production
High purity (≥98%) to support reproducible experimental outcomes
Batch verified for identity, purity, and structural consistency
Research Focus Areas
ARA-290 (Cibinetide) is commonly investigated in research involving:
Innate Repair Receptor (IRR) signaling
Neuroinflammation
Peripheral nerve biology
Tissue repair and regeneration
Inflammatory pathways
Oxidative stress
Cell survival mechanisms
Regenerative medicine
Brines M, Cerami A. The receptor that tames the innate immune response. Molecular Medicine. 2012;18:486-496.
https://doi.org/10.2119/molmed.2011.00414Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves symptoms of small fiber neuropathy. Molecular Medicine. 2015;21:17-28.
https://doi.org/10.2119/molmed.2014.00237Dahan A, Dunne A, Swartjes M, et al. ARA 290, a peptide derived from erythropoietin, produces tissue-protective effects in experimental and clinical studies. Pharmacology & Therapeutics. 2016.
Brines M, Patel NS, Villa P, et al. Nonerythropoietic derivatives of erythropoietin reduce tissue injury. Proceedings of the National Academy of Sciences (PNAS). 2008.